Retrospective Assessment of Carbonic Anhydrase Inhibitors in Topical or Episcleral Implant Form for the Treatment of Equine Glaucoma
Veterinary Ophthalmology · 2025
DOI: 10.1111/vop.70086 ↗Kurz gefasst
Fachartikel in der Zeitschrift Veterinary Ophthalmology, 2025. Verfasst von Emily K Tucker-Retter und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Sciences, College of Veterinary Medicine, North Carolina State University, Raleigh, North Carolina, USA. Hauptthemen laut MEDLINE: Carbonic Anhydrase Inhibitors, Horse Diseases, Glaucoma, Sulfonamides. Die Arbeit nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Objective
To assess whether topical carbonic anhydrase inhibitors (CAIs) with or without episcleral brinzolamide implants control intraocular pressure (IOP) in horses with glaucoma. Animals Studied 12 client‐owned horses diagnosed with glaucoma. Procedures Medical records of horses treated with topical CAIs for ≥ 14 days, with a subset receiving episcleral brinzolamide implants, were reviewed. Diagnosis, signalment, concurrent ocular disease, medications, IOP, visual status, and additional procedures were recorded. Treatment failure was defined as horses with IOP > 30 mmHg resulting in phthisis bulbi or requiring a procedure or enucleation.
Results
Secondary glaucoma was diagnosed in 8/12 (67%) eyes and primary glaucoma in 4/12 (33%) eyes. IOP was < 30 mmHg in 7/12 (58%) eyes after treatment with topical CAIs for a median of 28 days. Episcleral brinzolamide implants were placed in 7/12 eyes after a median of 58 days of medical therapy. Treatment failure occurred in 3/7 horses (43%) receiving brinzolamide implants at a median of 189 days and in 4/5 medical therapy‐only horses (80%) at a median of 51 days. While 6/12 eyes (50%) were visual at last follow‐up (median of 161 days), enucleation was the final outcome in 10/12 (83%) eyes.
Conclusions
Topical CAIs appear to result in temporary IOP control in a subset of horses, though some horses may be refractory. Episcleral brinzolamide implants may extend IOP control in horses with glaucoma, but prognosis for vision remains guarded and further optimization is needed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Sciences, College of Veterinary Medicine, North Carolina State University, Raleigh, North Carolina, USA.
- Hawaii Veterinary Vision, Inc., Honolulu, Hawaii, USA.
ORCID-Profile: Emily K Tucker-Retter, Brian Gilger, Annie Oh
Zitieren
APA
Tucker-Retter, E. K., Yamagata, M., Gilger, B., & Oh, A. (2025). Retrospective Assessment of Carbonic Anhydrase Inhibitors in Topical or Episcleral Implant Form for the Treatment of Equine Glaucoma. Veterinary Ophthalmology. https://doi.org/10.1111/vop.70086
Vancouver
Tucker-Retter EK, Yamagata M, Gilger B, Oh A. Retrospective Assessment of Carbonic Anhydrase Inhibitors in Topical or Episcleral Implant Form for the Treatment of Equine Glaucoma. Veterinary Ophthalmology. 2025. doi:10.1111/vop.70086
BibTeX
@article{TuckerRetter2025,
author = {Tucker-Retter, Emily K and Yamagata, Maya and Gilger, Brian and Oh, Annie},
title = {Retrospective Assessment of Carbonic Anhydrase Inhibitors in Topical or Episcleral Implant Form for the Treatment of Equine Glaucoma},
journal = {Veterinary Ophthalmology},
year = {2025},
doi = {10.1111/vop.70086}
}
EUVIMED